Numinus Completes Acquisition of Neurology Centre of Toronto

Canada NewsWire VANCOUVER, BC, Sept. 23, 2021 Acquisition strengthens clinic portfolio for mental health treatment using psychedelic-assisted therapies VANCOUVER, BC , Sept. 23, 2021 /CNW/ – Numinus Wellness Inc.  (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced it has closed its acquisition of the Neurology Centre of Toronto (NCT), a […]

HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics

The partnership is a integral step in the The Company’s path to market in the U.S., achieving one of its most important milestones to-date VANCOUVER, BC / ACCESSWIRE / September 23, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the […]

Mindset Pharma Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund (ETF)

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs, today announced that it has been included in the AdvisorShares Psychedelics ETF traded on the NYSE Arca under […]

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

NEW YORK , Sept. 23, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany . These investigator-initiated studies are being conducted as part of MindMed’s ongoing collaboration with the UHB Liechti […]